Influence of IL6R rs8192284 polymorphism status in disease activity in rheumatoid arthritis.
OBJECTIVE
To analyze the influence of IL6R rs8192284 polymorphism on the disease activity of rheumatoid arthritis (RA).


METHODS
Patients with RA (n = 281) were followed for a median of 4.2 years. A total of 1143 disease activity measurements using the 28-joint count Disease Activity Score (DAS28) were performed. A mixed-effect model was used to analyze the measurements.


RESULTS
A statistically significant interaction was observed between IL6R rs8192284 polymorphism and the presence of anticyclic citrullinated peptide (anti-CCP) antibodies (p = 0.008). An inverse relationship between the polymorphism and DAS28 was observed depending on anti-CCP status.


CONCLUSIONS
The anti-CCP status in patients with RA determines the association between the IL6R rs8192284 polymorphism and disease activity.
Lamas
José Ramón
JR
Rheumatology Service, Hospital Clínico San Carlos, 28040 Madrid, Spain.
Rodríguez-Rodríguez
Luis
L
Varadé
Jezabel
J
López-Romero
Pedro
P
Tornero-Esteban
Pilar
P
Abasolo
Lydia
L
Urcelay
Elena
E
Fernández-Gutiérrez
Benjamín
B
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000235:genetics* / Q000276:immunology / Q000503:physiopathology; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006304:Health Status; D006801:Humans; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000097:blood*; D020641:Polymorphism, Single Nucleotide; D019947:Receptors, Interleukin-6 / Q000097:blood / Q000235:genetics*; D012720:Severity of Illness Index; D015398:Signal Transduction
C508603:IL6R protein, human; D010456:Peptides, Cyclic; D019947:Receptors, Interleukin-6; C487763:cyclic citrullinated peptide